Neben K - Search Results

1

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.

Witzens M, Moehler T, Neben K, Fruehauf S, Hartschuh W, Ho AD, Goldschmidt H. Witzens M, et al. Among authors: neben k. Ann Hematol. 2004 Jul;83(7):467-70. doi: 10.1007/s00277-003-0804-0. Epub 2003 Nov 19. Ann Hematol. 2004. PMID: 14625789

2

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K, Moehler T, Hegenbart U, Ho AD, Goldschmidt H. Klein U, et al. Among authors: neben k. Ann Hematol. 2009 Jan;88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31. Ann Hematol. 2009. PMID: 18668241 Free article.

3

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.

Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H. Klein U, et al. Among authors: neben k. Ann Hematol. 2011 Apr;90(4):429-39. doi: 10.1007/s00277-010-1080-4. Epub 2010 Sep 21. Ann Hematol. 2011. PMID: 20857112

4

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M. Herth I, et al. Among authors: neben k. Exp Hematol. 2013 Mar;41(3):231-40. doi: 10.1016/j.exphem.2012.10.018. Epub 2012 Nov 8. Exp Hematol. 2013. PMID: 23142220 Free article. Clinical Trial.

5

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.

Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Moehler TM, et al. Among authors: neben k. Blood. 2001 Dec 15;98(13):3846-8. doi: 10.1182/blood.v98.13.3846. Blood. 2001. PMID: 11739195 Free article.

6

Angiogenesis in hematologic malignancies.

Moehler TM, Neben K, Ho AD, Goldschmidt H. Moehler TM, et al. Among authors: neben k. Ann Hematol. 2001 Dec;80(12):695-705. doi: 10.1007/s00277-001-0398-3. Epub 2001 Nov 14. Ann Hematol. 2001. PMID: 11797109 Review.

7

Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.

Schmitt S, Goldschmidt H, Storch-Hagenlocher B, Pham M, Fingerle-Rowson G, Ho AD, Neben K. Schmitt S, et al. Among authors: neben k. Int J Hematol. 2011 Jun;93(6):791-794. doi: 10.1007/s12185-011-0847-2. Epub 2011 May 7. Int J Hematol. 2011. PMID: 21553020

8

Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.

Schmitt S, Hielscher T, Baldus C, Neben K, Egerer G, Hillengaß J, Raab M, Hose D, Ho AD, Bergner R, Goldschmidt H, Moehler TM. Schmitt S, et al. Among authors: neben k. Int J Hematol. 2013 Jun;97(6):765-72. doi: 10.1007/s12185-013-1320-1. Epub 2013 Apr 25. Int J Hematol. 2013. PMID: 23616219

9

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H. Neben K, et al. Blood. 2002 Sep 15;100(6):2263-5. Blood. 2002. PMID: 12200397 Free article. Clinical Trial.

10

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Neben K, et al. Clin Cancer Res. 2002 Nov;8(11):3377-82. Clin Cancer Res. 2002. PMID: 12429624 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters